閉塞性細気管支炎症候群の世界市場レポート 2025年

閉塞性細気管支炎症候群市場規模は、今後数年間で力強い成長が見込まれます。2029年には22億3,000万米ドルに成長し、CAGRは8.9%となります。予測期間の成長は、肺移植手術の世界の増加、BOSに対する標的治療のパイプラインの拡大、希少疾病に対する政府と民間資金の増加、共同研究とライセンス契約の増加、個別化医療とバイオマーカーによるアプローチに対する需要の高まりに起因しています。この期間に予想される主要動向には、吸入ドラッグデリバリー技術の進歩、肺診断における人工知能の統合、精密医療における技術を活用した進歩、バイオインフォマティクスと臨床検査分析の開発、免疫調節療法の革新などがあります。

肺移植の増加は、今後数年間の閉塞性細気管支炎症候群（BOS）市場の成長を促進すると予想されます。肺移植は、呼吸機能を強化するために、疾患または機能不全の肺をドナーの健康な肺と置き換える外科的処置です。肺移植の増加は、成功率を向上させ合併症を減少させた外科的技術の進歩に起因しており、この処置はより安全で、より広く患者に提供されるようになりました。BOSが進行した患者にとって、肺移植は肺機能を回復させ呼吸困難を緩和する効果的な治療法です。例えば、2025年1月、米国を拠点とする非営利の科学・教育団体であるOrgan Procurement and Transplantation Network（臓器調達・移植ネットワーク）は、肺移植の割合が最も高い伸びを示し、2023年の3,026件から2024年には3,340件へと10.4％増加したと報告しています。このように、肺移植手術件数の増加が閉塞性細気管支炎症候群市場の拡大に大きく寄与しています。

臨床検査件数の増加が、今後数年間の閉塞性細気管支炎症候群（BOS）市場の成長を牽引すると予想されています。臨床検査とは、薬剤、デバイス、処置、行動療法などの医療介入の安全性、有効性、効果を評価するためにヒトを対象に実施される調査研究です。このような臨床検査の増加は、個別化医療に対する需要の高まりに後押しされており、標的治療や遺伝子ベースの治療を検証するためのより多くの研究が必要とされています。BOSの文脈では、臨床検査は、炎症を抑え肺機能を維持することを目的とした新しい治療法の評価において重要な役割を果たすと同時に、疾患の進行と治療の安全性の理解を進めています。例えば、英国を拠点とする産業団体である英国製薬工業協会（ABPI）は2023年11月、英国で開始された産業主催の臨床検査数が4.3％増加し、2021年の394件から2022年には411件に増加したと報告しています。したがって、臨床検査の成長は閉塞性細気管支炎症候群市場の拡大に大きく寄与しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、貿易戦争と関税、コロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の閉塞性細気管支炎症候群：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の閉塞性細気管支炎症候群市場：成長率分析
• 世界の閉塞性細気管支炎症候群市場の実績：規模と成長、2019～2024年
• 世界の閉塞性細気管支炎症候群市場の予測：規模と成長、2024～2029年、2034年
• 世界の閉塞性細気管支炎症候群：総潜在市場規模（TAM）

第6章 市場セグメンテーション

• 世界の閉塞性細気管支炎症候群市場：治療タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 医薬品
• 酸素療法
• 肺移植
• 世界の閉塞性細気管支炎症候群市場：診断別、実績と予測、2019～2024年、2024～2029年、2034年
• 肺機能検査
• 画像検査
• 肺生検
• その他
• 世界の閉塞性細気管支炎症候群市場：疾患タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 急性
• 慢性
• 世界の閉塞性細気管支炎症候群市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院
• 専門クリニック
• 診断センター
• その他
• 世界の閉塞性細気管支炎症候群市場、医薬品のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 免疫抑制剤
• コルチコステロイド
• 抗生物質
• 気管支拡大薬
• 抗炎症剤
• 世界の閉塞性細気管支炎症候群市場、酸素療法のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 持続酸素療法
• 間欠酸素療法
• ポータブル酸素療法
• 高圧酸素療法
• 世界の閉塞性細気管支炎症候群市場、肺移植のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 片肺移植
• 両肺移植
• 生体肺移植
• 再移植

第7章 地域別・国別分析

• 世界の閉塞性細気管支炎症候群市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の閉塞性細気管支炎症候群市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 閉塞性細気管支炎症候群市場：競合情勢
• 閉塞性細気管支炎症候群市場：企業プロファイル
  • Pfizer Inc.
  • Boehringer Ingelheim
  • University of California Health
  • Texas Children's Hospital
  • Incyte Corporation

第31章 その他の大手企業と革新的企業

• Apollo Hospitals
• Mallinckrodt Pharmaceuticals plc
• Zambon Company S.p.A.
• Fortis Healthcare
• St. Louis Children's Hospital
• Mayo Foundation for Medical Education and Research
• Medicover Hospitals
• Renovion Inc.
• Mereo BioPharma Group PLC
• OrphAI Therapeutics
• Koutif Therapeutics
• ArkBio
• Altavant Sciences
• Breath Therapeutics
• University of Alberta Hospital

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、戦略

• 閉塞性細気管支炎症候群市場、2029年：新たな機会を提供する国
• 閉塞性細気管支炎症候群市場、2029年：新たな機会を提供するセグメント
• 閉塞性細気管支炎症候群市場、2029年：成長戦略
  • 市場動向による戦略
  • 競合の戦略

第36章 付録

Bronchiolitis obliterans syndrome (BOS) is a chronic, progressive lung condition characterized by inflammation and scarring that lead to the narrowing of the small airways. It commonly occurs as a complication following lung or stem cell transplantation, signaling chronic graft rejection. Early diagnosis of BOS is vital to initiate timely treatment, slow disease progression, and preserve lung function.

The primary treatment options for bronchiolitis obliterans syndrome include medication, oxygen therapy, and lung transplantation. Medications help manage BOS by reducing inflammation, slowing disease advancement, and enhancing lung performance. Diagnosis involves various methods such as pulmonary function tests, imaging studies, lung biopsies, and others, tailored to different forms of the disease, including acute bronchiolitis and chronic bronchiolitis obliterans syndrome. The treatments are utilized across multiple end users, including hospitals, specialty clinics, diagnostic centers, and other healthcare facilities.

The bronchiolitis obliterans syndrome market research report is one of a series of new reports from The Business Research Company that provides bronchiolitis obliterans syndrome market statistics, including the bronchiolitis obliterans syndrome industry global market size, regional shares, competitors with the bronchiolitis obliterans syndrome market share, detailed bronchiolitis obliterans syndrome market segments, market trends, opportunities, and any further data you may need to thrive in the bronchiolitis obliterans syndrome industry. This bronchiolitis obliterans syndrome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The bronchiolitis obliterans syndrome market size has grown strongly in recent years. It will grow from $1.46 billion in 2024 to $1.59 billion in 2025 at a compound annual growth rate (CAGR) of 9.2%. Growth during the historical period can be attributed to the rising incidence of post-transplant complications, increased awareness among healthcare professionals, expanded use of immunosuppressive therapies, a heightened research focus on rare pulmonary conditions, and the growing adoption of advanced diagnostic imaging and lung function testing.

The bronchiolitis obliterans syndrome market size is expected to see strong growth in the next few years. It will grow to $2.23 billion in 2029 at a compound annual growth rate (CAGR) of 8.9%. Growth in the forecast period can be attributed to the global rise in lung transplant procedures, an expanding pipeline of targeted therapies for BOS, increased government and private funding for orphan diseases, growing collaborations and licensing agreements, and a rising demand for personalized medicine and biomarker-based approaches. Key trends expected during this period include progress in inhaled drug delivery technologies, the integration of artificial intelligence in pulmonary diagnostics, technology-enabled advancements in precision medicine, developments in bioinformatics and clinical trial analytics, and innovations in immunomodulatory therapies.

The increasing number of lung transplantations is anticipated to drive the growth of the bronchiolitis obliterans syndrome (BOS) market in the coming years. Lung transplantation is a surgical procedure in which a diseased or non-functioning lung is replaced with a healthy lung from a donor to enhance respiratory function. The rise in lung transplants is attributed to advancements in surgical techniques that have improved success rates and reduced complications, making the procedure safer and more widely available to patients. For individuals with advanced BOS, lung transplantation offers an effective treatment option by restoring lung function and easing breathing difficulties. For example, in January 2025, the Organ Procurement and Transplantation Network, a U.S.-based nonprofit scientific and educational organization, reported that lung transplants experienced the highest proportional growth, rising from 3,026 in 2023 to 3,340 in 2024-an increase of 10.4%. Thus, the rising number of lung transplant procedures is contributing significantly to the expansion of the bronchiolitis obliterans syndrome market.

The rising number of clinical trials is expected to drive the growth of the bronchiolitis obliterans syndrome (BOS) market in the coming years. Clinical trials are research studies conducted in humans to assess the safety, efficacy, and effectiveness of medical interventions, including drugs, devices, procedures, and behavioral therapies. This increase in clinical trials is fueled by the growing demand for personalized medicine, which necessitates more studies to validate targeted and gene-based treatments. In the context of BOS, clinical trials play a crucial role in evaluating new therapies that aim to reduce inflammation and preserve lung function, while also advancing the understanding of disease progression and treatment safety. For instance, in November 2023, the Association of the British Pharmaceutical Industry (ABPI), a UK-based trade group, reported a 4.3% increase in the number of industry-sponsored clinical trials launched in the UK, rising from 394 in 2021 to 411 in 2022. Therefore, the growth in clinical trials is contributing significantly to the expansion of the bronchiolitis obliterans syndrome market.

Leading companies in the bronchiolitis obliterans syndrome (BOS) market are concentrating on the development of advanced treatments such as at-home nebulized therapy to improve medication adherence and slow disease progression through targeted, continuous care. At-home nebulized therapy uses a nebulizer to convert liquid medication into a mist that can be inhaled directly into the lungs, offering a convenient and self-administered option for managing respiratory conditions from home. For example, in March 2023, Renovion, Inc., a U.S.-based clinical-stage pharmaceutical company, introduced ARINA-1, which received Fast Track Designation from the U.S. Food and Drug Administration (FDA). ARINA-1 is designed to prevent the progression of BOS in patients who have undergone bilateral lung transplants. This regulatory recognition highlights the therapy's potential to meet a critical unmet need in transplant medicine. The Fast Track status allows for more frequent interactions with the FDA and prioritizes ARINA-1 for accelerated development and review, reinforcing Renovion's commitment to advancing respiratory care through innovative, patient-centered treatments.

Major players in the bronchiolitis obliterans syndrome market are Pfizer Inc., Boehringer Ingelheim, University of California Health, Texas Children's Hospital, Incyte Corporation, Apollo Hospitals, Mallinckrodt Pharmaceuticals plc, Zambon Company S.p.A., Fortis Healthcare, St. Louis Children's Hospital, Mayo Foundation for Medical Education and Research, Medicover Hospitals, Renovion Inc., Mereo BioPharma Group PLC, OrphAI Therapeutics, Koutif Therapeutics, ArkBio, Altavant Sciences, Breath Therapeutics, University of Alberta Hospital.

North America was the largest region in the bronchiolitis obliterans syndrome market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the bronchiolitis obliterans syndrome market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The bronchiolitis obliterans syndrome market consists of revenues earned by entities providing services such as psychological counseling, patient monitoring and follow-up care, nutritional support, and pulmonary rehabilitation. The market value includes the value of related goods sold by the service provider or included within the service offering. The bronchiolitis obliterans syndrome market also includes sales of high-resolution CT (HRCT) scanner, oxygen concentrators, flexible bronchoscope, and invasive ventilators. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Bronchiolitis Obliterans Syndrome Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on bronchiolitis obliterans syndrome market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for bronchiolitis obliterans syndrome ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The bronchiolitis obliterans syndrome market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment Type: Medication; Oxygen Therapy; Lung Transplant
• 2) By Diagnosis: Pulmonary Function Tests; Imaging Tests; Lung Biopsy; Other Diagnosis
• 3) By Disease Type: Acute Bronchiolitis; Chronic Bronchiolitis Obliterans Syndrome
• 4) By End-User: Hospitals; Specialty Clinics; Diagnostic Centers; Other End-Users
• Subsegments:
• 1) By Medication: Immunosuppressants; Corticosteroids; Antibiotics; Bronchodilators; Anti-Inflammatory Agents
• 2) By Oxygen Therapy: Continuous Oxygen Therapy; Intermittent Oxygen Therapy; Portable Oxygen Therapy; Hyperbaric Oxygen Therapy
• 3) By Lung Transplant: Single Lung Transplant; Double Lung Transplant; Living Donor Lung Transplant; Retransplantation
• Companies Mentioned: Pfizer Inc.; Boehringer Ingelheim; University of California Health; Texas Children's Hospital; Incyte Corporation
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Bronchiolitis Obliterans Syndrome Market Characteristics

3. Bronchiolitis Obliterans Syndrome Market Trends And Strategies

4. Bronchiolitis Obliterans Syndrome Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Bronchiolitis Obliterans Syndrome Growth Analysis And Strategic Analysis Framework

• 5.1. Global Bronchiolitis Obliterans Syndrome PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Bronchiolitis Obliterans Syndrome Market Growth Rate Analysis
• 5.4. Global Bronchiolitis Obliterans Syndrome Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Bronchiolitis Obliterans Syndrome Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Bronchiolitis Obliterans Syndrome Total Addressable Market (TAM)

6. Bronchiolitis Obliterans Syndrome Market Segmentation

• 6.1. Global Bronchiolitis Obliterans Syndrome Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Medication
• Oxygen Therapy
• Lung Transplant
• 6.2. Global Bronchiolitis Obliterans Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pulmonary Function Tests
• Imaging Tests
• Lung Biopsy
• Other Diagnosis
• 6.3. Global Bronchiolitis Obliterans Syndrome Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Acute Bronchiolitis
• Chronic Bronchiolitis Obliterans Syndrome
• 6.4. Global Bronchiolitis Obliterans Syndrome Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Diagnostic Centers
• Other End-Users
• 6.5. Global Bronchiolitis Obliterans Syndrome Market, Sub-Segmentation Of Medication, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immunosuppressants
• Corticosteroids
• Antibiotics
• Bronchodilators
• Anti-Inflammatory Agents
• 6.6. Global Bronchiolitis Obliterans Syndrome Market, Sub-Segmentation Of Oxygen Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Continuous Oxygen Therapy
• Intermittent Oxygen Therapy
• Portable Oxygen Therapy
• Hyperbaric Oxygen Therapy
• 6.7. Global Bronchiolitis Obliterans Syndrome Market, Sub-Segmentation Of Lung Transplant, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Single Lung Transplant
• Double Lung Transplant
• Living Donor Lung Transplant
• Retransplantation

7. Bronchiolitis Obliterans Syndrome Market Regional And Country Analysis

• 7.1. Global Bronchiolitis Obliterans Syndrome Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Bronchiolitis Obliterans Syndrome Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Bronchiolitis Obliterans Syndrome Market

• 8.1. Asia-Pacific Bronchiolitis Obliterans Syndrome Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Bronchiolitis Obliterans Syndrome Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Bronchiolitis Obliterans Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Bronchiolitis Obliterans Syndrome Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Bronchiolitis Obliterans Syndrome Market

• 9.1. China Bronchiolitis Obliterans Syndrome Market Overview
• 9.2. China Bronchiolitis Obliterans Syndrome Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Bronchiolitis Obliterans Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Bronchiolitis Obliterans Syndrome Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Bronchiolitis Obliterans Syndrome Market

• 10.1. India Bronchiolitis Obliterans Syndrome Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Bronchiolitis Obliterans Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Bronchiolitis Obliterans Syndrome Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Bronchiolitis Obliterans Syndrome Market

• 11.1. Japan Bronchiolitis Obliterans Syndrome Market Overview
• 11.2. Japan Bronchiolitis Obliterans Syndrome Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Bronchiolitis Obliterans Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Bronchiolitis Obliterans Syndrome Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Bronchiolitis Obliterans Syndrome Market

• 12.1. Australia Bronchiolitis Obliterans Syndrome Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Bronchiolitis Obliterans Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Bronchiolitis Obliterans Syndrome Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Bronchiolitis Obliterans Syndrome Market

• 13.1. Indonesia Bronchiolitis Obliterans Syndrome Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Bronchiolitis Obliterans Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Bronchiolitis Obliterans Syndrome Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Bronchiolitis Obliterans Syndrome Market

• 14.1. South Korea Bronchiolitis Obliterans Syndrome Market Overview
• 14.2. South Korea Bronchiolitis Obliterans Syndrome Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Bronchiolitis Obliterans Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Bronchiolitis Obliterans Syndrome Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Bronchiolitis Obliterans Syndrome Market

• 15.1. Western Europe Bronchiolitis Obliterans Syndrome Market Overview
• 15.2. Western Europe Bronchiolitis Obliterans Syndrome Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Bronchiolitis Obliterans Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Bronchiolitis Obliterans Syndrome Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Bronchiolitis Obliterans Syndrome Market

• 16.1. UK Bronchiolitis Obliterans Syndrome Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Bronchiolitis Obliterans Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Bronchiolitis Obliterans Syndrome Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Bronchiolitis Obliterans Syndrome Market

• 17.1. Germany Bronchiolitis Obliterans Syndrome Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Bronchiolitis Obliterans Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Bronchiolitis Obliterans Syndrome Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Bronchiolitis Obliterans Syndrome Market

• 18.1. France Bronchiolitis Obliterans Syndrome Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Bronchiolitis Obliterans Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Bronchiolitis Obliterans Syndrome Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Bronchiolitis Obliterans Syndrome Market

• 19.1. Italy Bronchiolitis Obliterans Syndrome Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Bronchiolitis Obliterans Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Bronchiolitis Obliterans Syndrome Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Bronchiolitis Obliterans Syndrome Market

• 20.1. Spain Bronchiolitis Obliterans Syndrome Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Bronchiolitis Obliterans Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Bronchiolitis Obliterans Syndrome Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Bronchiolitis Obliterans Syndrome Market

• 21.1. Eastern Europe Bronchiolitis Obliterans Syndrome Market Overview
• 21.2. Eastern Europe Bronchiolitis Obliterans Syndrome Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Bronchiolitis Obliterans Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Bronchiolitis Obliterans Syndrome Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Bronchiolitis Obliterans Syndrome Market

• 22.1. Russia Bronchiolitis Obliterans Syndrome Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Bronchiolitis Obliterans Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Bronchiolitis Obliterans Syndrome Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Bronchiolitis Obliterans Syndrome Market

• 23.1. North America Bronchiolitis Obliterans Syndrome Market Overview
• 23.2. North America Bronchiolitis Obliterans Syndrome Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Bronchiolitis Obliterans Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Bronchiolitis Obliterans Syndrome Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Bronchiolitis Obliterans Syndrome Market

• 24.1. USA Bronchiolitis Obliterans Syndrome Market Overview
• 24.2. USA Bronchiolitis Obliterans Syndrome Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Bronchiolitis Obliterans Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Bronchiolitis Obliterans Syndrome Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Bronchiolitis Obliterans Syndrome Market

• 25.1. Canada Bronchiolitis Obliterans Syndrome Market Overview
• 25.2. Canada Bronchiolitis Obliterans Syndrome Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Bronchiolitis Obliterans Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Bronchiolitis Obliterans Syndrome Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Bronchiolitis Obliterans Syndrome Market

• 26.1. South America Bronchiolitis Obliterans Syndrome Market Overview
• 26.2. South America Bronchiolitis Obliterans Syndrome Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Bronchiolitis Obliterans Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Bronchiolitis Obliterans Syndrome Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Bronchiolitis Obliterans Syndrome Market

• 27.1. Brazil Bronchiolitis Obliterans Syndrome Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Bronchiolitis Obliterans Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Bronchiolitis Obliterans Syndrome Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Bronchiolitis Obliterans Syndrome Market

• 28.1. Middle East Bronchiolitis Obliterans Syndrome Market Overview
• 28.2. Middle East Bronchiolitis Obliterans Syndrome Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Bronchiolitis Obliterans Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Bronchiolitis Obliterans Syndrome Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Bronchiolitis Obliterans Syndrome Market

• 29.1. Africa Bronchiolitis Obliterans Syndrome Market Overview
• 29.2. Africa Bronchiolitis Obliterans Syndrome Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Bronchiolitis Obliterans Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Bronchiolitis Obliterans Syndrome Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Bronchiolitis Obliterans Syndrome Market Competitive Landscape And Company Profiles

• 30.1. Bronchiolitis Obliterans Syndrome Market Competitive Landscape
• 30.2. Bronchiolitis Obliterans Syndrome Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Boehringer Ingelheim Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. University of California Health Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Texas Children's Hospital Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Incyte Corporation Overview, Products and Services, Strategy and Financial Analysis

31. Bronchiolitis Obliterans Syndrome Market Other Major And Innovative Companies

• 31.1. Apollo Hospitals
• 31.2. Mallinckrodt Pharmaceuticals plc
• 31.3. Zambon Company S.p.A.
• 31.4. Fortis Healthcare
• 31.5. St. Louis Children's Hospital
• 31.6. Mayo Foundation for Medical Education and Research
• 31.7. Medicover Hospitals
• 31.8. Renovion Inc.
• 31.9. Mereo BioPharma Group PLC
• 31.10. OrphAI Therapeutics
• 31.11. Koutif Therapeutics
• 31.12. ArkBio
• 31.13. Altavant Sciences
• 31.14. Breath Therapeutics
• 31.15. University of Alberta Hospital

32. Global Bronchiolitis Obliterans Syndrome Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Bronchiolitis Obliterans Syndrome Market

34. Recent Developments In The Bronchiolitis Obliterans Syndrome Market

35. Bronchiolitis Obliterans Syndrome Market High Potential Countries, Segments and Strategies

• 35.1 Bronchiolitis Obliterans Syndrome Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Bronchiolitis Obliterans Syndrome Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Bronchiolitis Obliterans Syndrome Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer